234 related articles for article (PubMed ID: 23325880)
1. Drug companies should release data from all trials of licensed drugs, say MPs.
Hawkes N
BMJ; 2013 Jan; 346():f321. PubMed ID: 23325880
[No Abstract] [Full Text] [Related]
2. NICE is urged to make drug companies supply all trial data.
O'Dowd A
BMJ; 2012 Dec; 345():e8294. PubMed ID: 23223692
[No Abstract] [Full Text] [Related]
3. China cracks down on fake data in drug trials.
Cyranoski D
Nature; 2017 May; 545(7654):275. PubMed ID: 28516939
[No Abstract] [Full Text] [Related]
4. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
[TBL] [Abstract][Full Text] [Related]
5. Europe's drug regulator opens vaults of clinical-trials data.
Abbott A
Nature; 2016 Oct; 538(7626):440. PubMed ID: 27786232
[No Abstract] [Full Text] [Related]
6. Malfeasance on an industrial scale.
Prescrire Int; 2013 Feb; 22(135):32. PubMed ID: 23444493
[No Abstract] [Full Text] [Related]
7. Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS.
Kim J; Ross JS; Kapczynski A
JAMA; 2018 Jan; 319(1):21-22. PubMed ID: 29117365
[No Abstract] [Full Text] [Related]
8. Balancing government regulation against access to drugs: address to Seton Hall University School of Law, February 16, 2007.
Meron D
Seton Hall Law Rev; 2007; 37(4):929-39. PubMed ID: 18363219
[No Abstract] [Full Text] [Related]
9. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
Ochs A
Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
[No Abstract] [Full Text] [Related]
10. Predictable materiality: a need for common criteria governing the disclosure of clinical trial results by publicly-traded pharmaceutical companies.
Cohen K; Cormier JW; Davar MV
J Contemp Health Law Policy; 2013; 29(2):201-32. PubMed ID: 23837261
[No Abstract] [Full Text] [Related]
11. Access before approval--a right to take experimental drugs?
Okie S
N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
[No Abstract] [Full Text] [Related]
12. Physician specific prescribing information.
Somberg J
Am J Ther; 2006; 13(6):465. PubMed ID: 17122524
[No Abstract] [Full Text] [Related]
13. Good pharma? Bad pharma? Better pharma.
Hardman M
J R Coll Physicians Edinb; 2014; 44(4):269-72. PubMed ID: 25516893
[No Abstract] [Full Text] [Related]
14. The right to a trial: Should dying patients have access to experimental drugs?
Groopman J
New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
[No Abstract] [Full Text] [Related]
15. Russian drug law hinders clinical trials.
Katsnelson A
Nature; 2012 Jan; 481(7381):250. PubMed ID: 22258585
[No Abstract] [Full Text] [Related]
16. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
[No Abstract] [Full Text] [Related]
17. Data sharing will pay dividends.
Nature; 2014 Jan; 505(7482):131. PubMed ID: 24409508
[No Abstract] [Full Text] [Related]
18. Maine law requires drug companies to provide clinical trial data.
Appell D
J Natl Cancer Inst; 2005 Sep; 97(17):1246. PubMed ID: 16145043
[No Abstract] [Full Text] [Related]
19. Putting GlaxoSmithKline to the test over paroxetine.
Doshi P
BMJ; 2013 Nov; 347():f6754. PubMed ID: 24222673
[No Abstract] [Full Text] [Related]
20. Regulating the market in human research participants.
Lemmens T; Miller PB
PLoS Med; 2006 Aug; 3(8):e330. PubMed ID: 16866575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
